Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard
treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus
has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in
patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.